News & Media
ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy
- UM171 Cell Therapy has been granted an International Nonproprietary Name (INN) of “dorocubicel” on the INN Recommended List issued by the World Health Organization (WHO) - The U.S. Food and Drug Administration (FDA) has granted UM171 Cell Therapy (INN-dorocubicel)...
ExCellThera announces new UM171 data to be presented at ASH 2023
MONTREAL, November 3, 2023 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and fitness, announced today several UM171 presentations, including an oral session on new data from Phase 2 studies of investigational UM171 cell therapy in...
UM171-Expanded Cell Therapy improves outcomes compared with other graft sources: Real-world evidence
MONTREAL, August 8, 2023 — Cordex Biologics Inc., an ExCellThera Company, announced today the recent publication in Blood Advances of results from a safety and efficacy retrospective analysis …